Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393793 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL28339868 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL28430028 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL678577 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL27141492 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL5401819 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL31399648 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL16782313 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL10603119 | 1.00 | CES2 (0.55) | CES2DNM1CES1MEN1FAAH | |
| SCHEMBL29945608 | 0.98 | CES2 (0.53) | CES2DNM1CES1MEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326708-A1 | LONG-ACTING SPLEEN-TARGETING CATIONIC LIPID COMPOUND COMPRISING BENZENE RING STRUCTURE, COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING YOUCAREKECHUANG PHARMACEUTICAL TECH CO LTD (CN) | 2025-10-23 | — | — | US | claimed |
| CN-115281192-B | Preparation and method for improving photosynthetic efficiency and/or drought resistance of vegetable crops | 海南浙江大学研究院 | 2024-10-08 | — | — | CN | claimed |
| CN-115281192-A | Preparation and method for improving photosynthetic efficiency and/or drought resistance of vegetable crops | 海南浙江大学研究院 | 2022-11-04 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| CN-109689045-A | Purposes of the topical formulations of cannboid in treatment epidermolysis bollosa and Related connective tissue illness | 因美制药公司 | 2019-04-26 | — | — | CN | claimed |
| CN-105191937-B | Application of stearoyl ethanolamine in plant botrytis resistance improvement | 浙江大学 | 2017-04-12 | — | — | CN | claimed |
| WO-2013063263-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | LYCUS LLC (US) | 2013-05-02 | — | — | WO | claimed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| CN-115281192-B | Preparation and method for improving photosynthetic efficiency and/or drought resistance of vegetable crops | 海南浙江大学研究院 | 2024-10-08 | — | — | CN | disclosed |
| CN-115281192-B | Preparation and method for improving photosynthetic efficiency and/or drought resistance of vegetable crops | 海南浙江大学研究院 | 2024-10-08 | — | — | CN | disclosed |
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| CN-117092238-A | Endogenous cannabinoid biomarker composition, detection method and application thereof | 上海中医药大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-105191937-A | Application of stearoyl ethanolamine in plant botrytis resistance improvement | UNIV ZHEJIANG | 2015-12-30 | — | — | CN | disclosed |
| CN-105191937-A | Application of stearoyl ethanolamine in plant botrytis resistance improvement | UNIV ZHEJIANG | 2015-12-30 | — | — | CN | disclosed |
| CN-105191937-A | Application of stearoyl ethanolamine in plant botrytis resistance improvement | UNIV ZHEJIANG | 2015-12-30 | — | — | CN | disclosed |
| WO-2013063263-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN | LYCUS LLC (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2011089240-A1 | DIAGNOSTIC METHOD FOR ENDOMETRIAL RECEPTIVITY | EQUIPO IVI INVESTIGACIÓN S.L. (ES) | 2011-07-28 | — | — | WO | disclosed |
| EP-2146739-A2 | METHODS OF IMMUNE OR HEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER, CANCER SYMPTOMS, OR THE SYMPTOMS OF CANCER TREATMENTS | Fontera Co-Operative Group Limited (NZ) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008140335-A2 | METHODS OF IMMUNE OR HEMATOLOGICAL ENHANCEMENT, INHIBITING TUMOUR FORMATION OR GROWTH, AND TREATING OR PREVENTING CANCER, CANCER SYMPTOMS, OR THE SYMPTOMS OF CANCER TREATMENTS | FONTERRA CO-OPERATIVE GROUP LIMITED (NZ) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326708-A1 | LONG-ACTING SPLEEN-TARGETING CATIONIC LIPID COMPOUND COMPRISING BENZENE RING STRUCTURE, COMPOSITION COMPRISING SAME, AND USE THEREOF | CD47, MYD88, SGMS1 | CES2 2384/4885DNM1 3190/4885CES1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.